% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Derigs:282877,
      author       = {P. Derigs and W. A. Bethge and I. Krämer and U. Holtick
                      and B. von Tresckow$^*$ and F. Ayuk and O. Penack and V.
                      Vucinic and M. von Bonin and C. Baldus and D. Mougiakakos
                      and G. Wulf and U. Schnetzke and M. Stelljes and M. Fante
                      and R. Schroers and N. Kroeger and P. Dreger},
      title        = {{L}ong-{T}erm {S}urvivors {A}fter {F}ailure of {CAR}-{T}
                      {C}ell {T}herapy for {L}arge {B}-{C}ell {L}ymphoma: {A}
                      {R}ole for {A}llogeneic {H}ematopoietic {C}ell
                      {T}ransplantation? {A} {GLA}/{DRST} {A}nalysis.},
      journal      = {Transplantation and cellular therapy},
      volume       = {29},
      number       = {12},
      issn         = {2666-6375},
      address      = {[Amsterdam]},
      publisher    = {Elsevier B. V.},
      reportid     = {DKFZ-2023-01879},
      pages        = {750-756},
      year         = {2023},
      note         = {2023 Dec;29(12):750-756},
      abstract     = {The outcome of patients with large B-cell lymphoma (LBCL)
                      who relapse or progress after CD19-directed CAR-T cell
                      therapy administered as salvage therapy beyond the second
                      treatment line is poor. However, a minority of patients
                      become long-term survivors despite CAR-T failure. The German
                      Lymphoma Alliance (GLA) has proposed a hierarchical
                      management algorithm for CAR-T failure in LBCL, aiming at
                      allogeneic hematopoietic cell transplantation (alloHCT) as
                      definite therapy in eligible patients.The purpose of this
                      study was to investigate characteristics, relapse patterns
                      and management strategies in long-term survivors after CAR-T
                      failure with particular focus on feasibility and outcome of
                      alloHCT.Retrospective analysis of all evaluable patients
                      with relapse/progression event (REL) observed in a previous
                      reported GLA sample (Bethge et al, Blood 2022) between
                      November 2018 and May 2021.REL occurred in 214 of 356
                      patients $(60\%)$ having undergone CAR-T for LBCL in the
                      previous GLA study. For 143 of these 214 patients $(67\%)$
                      an evaluable dataset was available. 26 of 143 patients
                      $(18\%)$ survived 12 months or longer from REL, 109 $(76\%)$
                      died within the first year after REL, and 8 patients $(6\%)$
                      were alive but had not reached the 12-months landmark.
                      Long-term survivors had more favorable pre-CAR-T features,
                      had a longer interval between CAR-T and REL, and had more
                      often received a tumor biopsy post CAR-T failure, whereas
                      the choice of the first salvage regimen had no impact.
                      AlloHCT was feasible in 40 of 53 patients $(75\%)$ intended
                      and resulted in a 12-month post-transplant overall survival
                      of $36\%$ in those patients who underwent transplant with
                      sensitive or untreated REL.AlloHCT after CAR-T failure in
                      LBCL is feasible and may be an important contributor to
                      long-term survival although selection bias has to be taken
                      into account. Thus, alloHCT should be considered as a
                      reasonable treatment option in eligible patients in this
                      setting. Since the overall outlook after CAR-T failure
                      nevertheless remains poor, novel effective therapeutic
                      approaches are needed, either for allowing long-term disease
                      control per se, or for improving the preconditions for
                      successful alloHCT.},
      keywords     = {Allogeneic Hematopoietic Cell Transplantation (Other) /
                      CAR-T (Other) / Lymphoma (Other) / Relapse (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37709204},
      doi          = {10.1016/j.jtct.2023.09.008},
      url          = {https://inrepo02.dkfz.de/record/282877},
}